Illumina Launches the Illumina Accelerator Program, World’s First Genomics Incubator

  Illumina Launches the Illumina Accelerator Program, World’s First Genomics
  Incubator

Yuri Milner to Invest in Every Startup Joining the Accelerator, Silicon Valley
                     Bank to Provide Additional Financing

Business Wire

SAN DIEGO -- February 12, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the Illumina
Accelerator Program, the world’s first business accelerator focused solely on
creating an innovation ecosystem for the genomics industry. Its goal is to
speed the time to market and lower the barriers to entry for entrepreneurs,
start-ups and early stage companies working on scientifically and commercially
promising next-generation sequencing (NGS) applications.

Through the accelerator’s six-month program, Illumina will provide invited
participants with technology and business guidance and $100,000 in support,
including access to sequencing systems and reagents, as well as fully
operational lab space in close proximity to the company’s planned R&D
facilities in San Francisco’s Mission Bay. Initial partners include prominent
technology investor Yuri Milner, who will offer each participating company
$100,000 in exchange for convertible notes, and Silicon Valley Bank, which
intends to provide banking services and credit to each participating company.

“Next-generation sequencing has reached the lift-off stage. I’m excited to
support this endeavor promoting innovation and entrepreneurship in the
genomics ecosystem and look forward to working with Illumina, the global
leader in sequencing technology,” said Yuri Milner.

“As an organization that supports life science entrepreneurs across all stages
of growth, wesee some of the greatest funding needs at the earliest
stages.For this reason, we're excited to be partnering with Illumina and Yuri
Milner in the launch of this accelerator program that can help provide the
selected companieswith the financial resources to continue along their
development path and increase their likelihood of success,” said Jennifer
Friel Goldstein, Managing Director and National Practice Leader of
Biotechnology & Diagnostics at Silicon Valley Bank.

“The dramatic reduction in the cost of sequencing has enabled the scientific
and business communities to address an increasingly broad range of research
and clinical opportunities. We’ve only begun to scratch the surface, however,
and we’re excited to foster the next generation of genomics innovators working
in areas as diverse as agriculture, forensics, consumer genetics and
diagnostics. The Illumina Accelerator Program will make it easier for them to
validate and create NGS applications and bring these solutions to market,”
said Mostafa Ronaghi, Illumina’s Senior Vice President and Chief Technology
Officer.

In addition to funding, technology access and mentorship, accelerator
participants will have access to Illumina’s global customer and venture
networks and partner support services including financial modeling,
forecasting, and legal and human resource assistance. They will also receive
licensing and technology transfer support and pitch preparation support.

Through a competitive process, the Illumina Accelerator Program will select up
to three companies to participate in each six-month session per year.
Applications are due May 16, 2014 for the inaugural session that begins August
1, 2014. To apply, visit www.illumina.com/accelerator.

AboutIllumina

Illumina(www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

About Silicon Valley Bank

Silicon Valley Bank is the premier bank for technology, life sciences,
cleantech, venture capital, private equity and premium wine businesses. SVB
provides industry knowledge and connections, financing, treasury management,
corporate investment and international banking services to its clients
worldwide through 28 U.S. offices and six international operations. (SIVB)
www.svb.com.

Silicon Valley Bank is the California bank subsidiary and the commercial
banking operation of SVB Financial Group. Banking services are provided by
Silicon Valley Bank, a member of the FDIC and the Federal Reserve System. SVB
Financial Group is also a member of the Federal Reserve System. Nothing in
this press release is an offer or a commitment to provide services or lines of
credit to any individual or company. All individuals and companies must meet
Silicon Valley Bank underwriting, know-your-client and other criteria before
Silicon Valley Bank will accept them as clients and extend bank products and
services, including extensions of credit.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.